Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.67 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL500203 | 0.98 | BCAT2 (0.65) | BCAT2LTB4R2TAAR1PPARGKEAP1 | |
| SCHEMBL30207677 | 0.87 | BCAT2 (0.69) | BCAT2LTB4R2PPARGCHEK1PLA2G2A | |
| SCHEMBL30933610 | 0.87 | BCAT2 (0.69) | BCAT2LTB4R2PPARGKEAP1NFE2L2 | |
| SCHEMBL5878337 | 0.87 | BCAT2 (0.87) | BCAT2LTB4R2PPARGKEAP1NFE2L2 | |
| SCHEMBL3629995 | 0.86 | LTB4R2 (0.57) | BCAT2LTB4R2TAAR1 | |
| SCHEMBL20946451 | 0.85 | BCAT2 (0.61) | BCAT2KEAP1NFE2L2CHEK1PLA2G2A | |
| SCHEMBL16149659 | 0.85 | BCAT2 (0.91) | BCAT2KEAP1NFE2L2CHEK1PARP1 | |
| SCHEMBL30582476 | 0.85 | BCAT2 (0.83) | BCAT2LTB4R2PPARGKEAP1NFE2L2 | |
| SCHEMBL5902171 | 0.84 | BCAT2 (0.65) | BCAT2LTB4R2PPARGKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL6179887 | 0.84 | LTB4R2 (0.56) | BCAT2LTB4R2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483582-A | Azepine Cabbeen palladium complex crystal and its synthetic method and preparing the application in amide compound | UNIV SHAANXI NORMAL | 2019-11-22 | — | — | CN | disclosed |
| CN-108440328-A | A kind of amide takes off boc-protected method | 常熟理工学院 | 2018-08-24 | — | — | CN | disclosed |
| US-8106216-B2 | Process for the preparation of Irbesartan | AUROBINDO PHARMA LTD. (IN) | 2012-01-31 | — | — | US | disclosed |
| US-8106216-B2 | Process for the preparation of Irbesartan | AUROBINDO PHARMA LTD. (IN) | 2012-01-31 | — | — | US | disclosed |
| US-20100056797-A1 | Process for the Preparation of Irbesartan | AUROBINDO PHARMA LTD (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20100056797-A1 | Process for the Preparation of Irbesartan | AUROBINDO PHARMA LTD (IN) | 2010-03-04 | — | — | US | disclosed |
| WO-2007122508-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF IRBESARTAN | AUROBINDO PHARMA LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
| EP-1789409-A2 | SULFONAMIDES AND USES THEREOF | Elixir Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005097788-A2 | SULFONAMIDES AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| CN-1058710-C | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-11-22 | — | — | CN | disclosed |
| CN-1098406-A | New benzamide derivatives and method for making thereof and the pharmaceutical composition that contains them | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | BCAT2 238/4885LTB4R2 2432/4885TAAR1 3902/4885 |
| US-20100056797-A1 | Process for the Preparation of Irbesartan | AGTR1, REN, AGTR2 | BCAT2 2272/4885LTB4R2 2018/4885TAAR1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.